epratuzumab

Known as: monoclonal antibody LL2, LL2 monoclonal antibody, humanised anti-CD22 antibody 
A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of… (More)

Topic mentions per year

Topic mentions per year

1991-2017
010203019912017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
PURPOSE To determine the tolerability and serum concentration of epratuzumab, a humanized monoclonal antibody targeting CD22… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Epratuzumab is a humanized anti-CD22 monoclonal antibody currently in clinical trials for treatment of non-Hodgkin lymphoma (NHL… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
B cells play an important role in the pathogenesis of systemic lupus erythematosus (SLE), so the safety and activity of anti-B… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
This open-label, phase I/II study investigated the safety and efficacy of epratuzumab, a humanised anti-CD22 monoclonal antibody… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2006
2006
PURPOSE A multicenter, single-arm study examining efficacy and toxicity of epratuzumab combined with rituximab was conducted in… (More)
Is this relevant?
2005
2005
PURPOSE To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE A new humanized anti-CD20 monoclonal antibody (MAb), IMMU-106, was evaluated to elucidate its action as an antilymphoma… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE Epratuzumab is a novel humanized antihuman CD22 IgG1 antibody that has recently shown promising clinical activity, both… (More)
Is this relevant?